NASDAQ$ROIV
Roivant Sciences Ltd · Q3 2026 earnings
Q3 2026 earnings · · Before market open · Investor relations
Briefing
Roivant reported a quarterly net loss while advancing multiple late-stage clinical programs.
Roivant posted minimal revenue and a net loss in Q3 fiscal 2026 as the company continued to invest heavily in R&D to advance its clinical pipeline, while maintaining a strong liquidity position.
- Revenue remained minimal as the company focused on pipeline development.
- R&D spending increased year over year driven by late-stage programs.
- The company reported a net loss for the quarter.
- Liquidity remained strong with substantial cash and marketable securities.
Headline financials
Revenue & EPS history
Roivant Sciences · Revenue · Quarterly
$2M
Forward guidance
Management highlighted continued clinical momentum and sufficient liquidity to fund operations into profitability.
Tailwinds
- Multiple late-stage clinical programs progressing.
- Positive Phase 2 data for brepocitinib in cutaneous sarcoidosis.
- NDA submission completed for dermatomyositis indication.
- Strong cash and marketable securities balance.
- Several key clinical readouts expected in 2026.
Headwinds
- Continued operating losses expected near term.
- High R&D expense requirements.
- Dependence on clinical trial outcomes.
- Regulatory approval risk across pipeline assets.
- Limited near-term revenue generation.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2026
+3.3%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.4%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+22.1%
Q3 2026
Best reaction
-5.5%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +14.9% | — | — | |
| Q3 2026 | +22.1% | +26.8% | +36.1% | |
| Q2 2026 | +2.6% | -1.6% | -1.8% | |
| Q1 2026 | -2.8% | +3.1% | +19.8% | |
| Q4 2025 | +6.4% | +5.9% | +7.3% | |
| Q4 2024 | -3.4% | +0.0% | -1.5% | |
| Q3 2024 | +4.1% | +6.6% | -5.9% | |
| Q2 2024 | +5.6% | +1.8% | +22.7% | |
| Q1 2024 | -5.2% | -6.1% | -3.5% | |
| Q4 2023 | +9.4% | +7.8% | +28.8% | |
| Q3 2023 | +9.7% | +8.2% | +7.8% | |
| Q2 2023 | +7.4% | -3.1% | +39.9% | |
| Q1 2023 | -5.5% | -15.3% | -15.8% | |
| Q4 2022 | -4.1% | -5.6% | -11.8% | |
| Q3 2021 | +5.1% | -3.2% | -25.4% | |
| Q3 2022 | +5.4% | -3.2% | -25.4% | |
| Q2 2022 | -2.4% | -4.8% | +6.8% | |
| Q2 2021 | -3.8% | -4.8% | +6.8% | |
| Q1 2021 | +0.1% | +0.7% | -38.7% | |
| Q1 2022 | +0.0% | +0.7% | -38.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro